Get the Stockscreener App
13.00
2.48%
-0.33
After Hours:
13.00
Corbus Pharmaceuticals Holdings Inc stock is traded at $13.00, with a volume of 977.46K.
It is down -2.48% in the last 24 hours and down -19.15% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$13.33
Open:
$13.14
24h Volume:
977.46K
Relative Volume:
1.47
Market Cap:
$158.33M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.1818
EPS:
-11
Net Cash Flow:
$-36.86M
1W Performance:
-13.79%
1M Performance:
-19.15%
6M Performance:
-69.53%
1Y Performance:
+150.00%
1-Day Range:
$12.93
$13.46
1-Week Range:
$12.90
$15.00
52-Week Range:
$5.0877
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
13.00 | 158.33M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $62.00 - MarketBeat
(CRBP) Investment Report - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Mizuho remains bullish on Corbus stock, sees encouraging outlook for Nectin-4 ADC - Investing.com Canada
Charles Schwab Investment Management Inc. Buys 64,800 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals' SWOT analysis: stock's potential in cancer and obesity - Investing.com
Corbus Pharmaceuticals Holdings Inc. stock remains steady Friday, underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus begins phase 1 trial for advanced solid tumors By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus begins phase 1 trial for advanced solid tumors - Investing.com
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - The Manila Times
Corbus Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Corbus Pharma Launches Phase 1 Trial for Novel Cancer Immunotherapy CRB-601 - StockTitan
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential - MSN
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Trading (CRBP) With Integrated Risk Controls - Stock Traders Daily
Walleye Capital LLC Sells 113,428 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
FDA fast tracks Corbus drug for cervical cancer treatment By Investing.com - Investing.com Canada
Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits - Quantisnow
Piper Sandler Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Overweight Recommendation - MSN
HighVista Strategies LLC Acquires 36,499 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
FDA fast tracks Corbus drug for cervical cancer treatment - Investing.com
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewswire
Corbus Pharma Secures FDA Fast Track Status for Cancer Drug CRB-701 - StockTitan
CRBP (Corbus Pharmaceuticals Holdings) Financial Strength : 8 (As of Sep. 2024) - GuruFocus.com
Corbus Pharmaceuticals stock rated Overweight, CRB-701 could drive solid tumor efficacy - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus, Viking initiated at overweight by Piper Sandler (NASDAQ:VKTX) - Seeking Alpha
CRBP (Corbus Pharmaceuticals Holdings) Enterprise Value : $61.43 Mil (As of Dec. 02, 2024) - GuruFocus.com
Victory Capital Management Inc. Boosts Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Acuta Capital Partners LLC Reduces Stock Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now - Insider Monkey
CRBP (Corbus Pharmaceuticals Holdings) Change In Working Ca - GuruFocus.com
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Rating of "Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference - Investing.com Australia
CRBPCorbus Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Corbus Pharmaceuticals to Present at Evercore HealthCONx Conference in December | CRBP Stock News - StockTitan
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):